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CORRESPONDENCE 
Generic prescribing for epilepsy. Is it safe? 
Dear Sir, 
The report by Crawford et al makes little mention of 
sources of error in their study. The General Practices 
involved were selected twice; first by responding to 
the research team at all, and secondly by speed of 
response. Only 40 of 556 Practices made it over both 
hurdles! This would seem an effective means of se- 
lecting 40 Practices with an enthusiastic interest in 
epilepsy. What were the policies of the Practices who 
entered the study on generic prescribing for epilepsy? 
From these practices 2285 people with epilepsy 
were contacted and asked to complete a question- 
naire, of whom 58.8% responded. A switch of anti- 
convulsant, from generic to brand or brand to generic, 
was experienced by 251 people but we are not told 
from the GPs’ records how many switches actually 
occurred or what proportion of switches were generic 
to brand. Patients who perceived problems would be 
more likely to respond to the questionnaire and to 
remember switches. 
The basis for the claim that switches produced sig- 
nificant health problems is not clear. Increased sick 
leave and loss of employment are discussed, but the 
study gives no data on whether patients who perceive 
problems during the switch consulted their GPs or 
missed time off work. The basis for the GPs ‘validat- 
ing’ problems after the switch is not clear. 
A critical eye might perceive that, starting with the 
epilepsy population of the Yorkshire region-perhaps 
20000 patients, this study identified 21 people who 
felt poorly at a time which coincided with a switch 
of medication. 
Epilepsy is a very variable condition. Seizures 
change in frequency unpredictably even on constant 
medication. People with epilepsy are as subject to 
the placebo influence of changes in their medication 
as anyone else. UncontrolIed and highly selected re- 
ports do nothing to inform the debate about generic 
prescribing. 
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Post-mortem determination of anticonvuisant 
concentrations and lung oedema in the sudden, 
unexpected death of epileptics 
Dear Sir, now?‘. We would like to comment on this. Referring 
to a previous paper’ the authors questionned the relia- 
In Seizure 1996; 5: 235-238, Lina Nashef and bility of antiepileptic drug concentrations in posfmor- 
J.W.A.S. Sander published an article entitled: ‘Sud- tul samples. But, four recent findings strongly favour 
den unexpected deaths in epilepsy-where are we the relevance and reproducibility of post-mortem de- 
